TY - JOUR
T1 - Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis
T2 - post hoc analysis of three randomised clinical trials
AU - McInnes, Iain B.
AU - Ostor, Andrew J.K.
AU - Mease, Philip J.
AU - Tillett, William
AU - Baraliakos, Xenofon
AU - De Vlam, Kurt
AU - Bessette, Louis
AU - Lippe, Ralph
AU - Maniccia, Anna
AU - Feng, Dai
AU - Gao, Tianming
AU - Zueger, Patrick
AU - Saffore, Christopher
AU - Kato, Koji
AU - Song, In Ho
AU - Deodhar, Atul
N1 - Publisher Copyright:
©
PY - 2022/3/24
Y1 - 2022/3/24
N2 - Objective Evaluate the effect of upadacitinib on pain outcomes in patients with active psoriatic arthritis (PsA) or ankylosing spondylitis (AS) across 3 randomised trials (SELECT-PsA 1 and 2 for PsA; SELECT-AXIS 1 for AS). Methods Patients were randomised to upadacitinib 15 mg once daily or placebo (all 3 studies), or adalimumab 40 mg every other week (SELECT-PsA 1 only). Pain outcomes included proportion of patients achieving ≥30%, ≥50% and ≥70% reduction from baseline in patient global assessment of pain and other end points. Results A higher proportion of patients receiving upadacitinib versus placebo achieved ≥30%, ≥50% and ≥70% reduction in pain end points as early as week 2; these improvements with upadacitinib were generally sustained or increased through year 1 (PsA 1/2 studies: 64%/48%, 58%/42% and 38%/22%, respectively; SELECT-AXIS 1 study: 76%, 72% and 54%). Results were similar with adalimumab in PsA 1 (59%, 49% and 32%). Patients who switched from placebo to upadacitinib 15 mg were able to reach a similar level of improvement as the continuous upadacitinib groups by year 1 (PsA 1/2 studies: 46%-60%, 35%-49% and 15%-34%; AS study: 83%, 72% and 46%). Results were similar with other pain end points. Conclusion Rapid and sustained improvements in pain outcomes across several end points were consistently shown with upadacitinib over 1 year in patients with active PsA or AS who had either inadequate response to prior non-biologic or biologic disease-modifying antirheumatic drugs (PsA studies) or were biologic-naïve with inadequate response to non-steroidal anti-inflammatory drugs (AS study).
AB - Objective Evaluate the effect of upadacitinib on pain outcomes in patients with active psoriatic arthritis (PsA) or ankylosing spondylitis (AS) across 3 randomised trials (SELECT-PsA 1 and 2 for PsA; SELECT-AXIS 1 for AS). Methods Patients were randomised to upadacitinib 15 mg once daily or placebo (all 3 studies), or adalimumab 40 mg every other week (SELECT-PsA 1 only). Pain outcomes included proportion of patients achieving ≥30%, ≥50% and ≥70% reduction from baseline in patient global assessment of pain and other end points. Results A higher proportion of patients receiving upadacitinib versus placebo achieved ≥30%, ≥50% and ≥70% reduction in pain end points as early as week 2; these improvements with upadacitinib were generally sustained or increased through year 1 (PsA 1/2 studies: 64%/48%, 58%/42% and 38%/22%, respectively; SELECT-AXIS 1 study: 76%, 72% and 54%). Results were similar with adalimumab in PsA 1 (59%, 49% and 32%). Patients who switched from placebo to upadacitinib 15 mg were able to reach a similar level of improvement as the continuous upadacitinib groups by year 1 (PsA 1/2 studies: 46%-60%, 35%-49% and 15%-34%; AS study: 83%, 72% and 46%). Results were similar with other pain end points. Conclusion Rapid and sustained improvements in pain outcomes across several end points were consistently shown with upadacitinib over 1 year in patients with active PsA or AS who had either inadequate response to prior non-biologic or biologic disease-modifying antirheumatic drugs (PsA studies) or were biologic-naïve with inadequate response to non-steroidal anti-inflammatory drugs (AS study).
KW - Arthritis, Psoriatic
KW - Patient Reported Outcome Measures
KW - Spondylitis, Ankylosing
UR - http://www.scopus.com/inward/record.url?scp=85127036572&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127036572&partnerID=8YFLogxK
U2 - 10.1136/rmdopen-2021-002049
DO - 10.1136/rmdopen-2021-002049
M3 - Article
C2 - 35332058
AN - SCOPUS:85127036572
SN - 2056-5933
VL - 8
JO - RMD open
JF - RMD open
IS - 1
M1 - e002049
ER -